nach oben

Annals of Hematology

Erschienen in:

29.08.2018 | Original Article

Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression

verfasst von: Zhao Xiaosu, Cao Leqing, Qin Yazhen, Wang Yu, Zhang Xiaohui, Xu Lanping, Huang Xiaojun, Chang Yingjun

Erschienen in: Annals of Hematology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Ninety acute myeloid leukemia (AML) patients with inv(16) were monitored CBFβ/MYH11 transcript around allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 23 patients received HLA-matched sibling donor transplantation (MSDT) and 67 patients received unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were analyzed in this study. Patients were divided into four groups based on CBFβ/MYH11 expression prior to transplantation (pre-MRD): with negative (group 1)/positive (group 2) pre-MRD before MSDT; with negative (group 3)/positive (group 4) pre-MRD before haplo-HSCT. The results showed that patients in group 2 had the highest cumulative incidence of relapse (2-year CIR, 40.7%), the lowest leukemia-free survival (2-year LFS, 50.8%), and overall survival (2-year OS, 62.5%). The other three groups of patients had comparable outcomes. The patients were also classified into the other three groups according to CBFβ/MYH11 value of + 1 month after transplantation: group 5: pre- and post-transplant MRD were both negative; group 6: the value of post-transplant MRD was lower than 0.2%; group 7: the value of post-transplant MRD was higher than 0.2%. Group 7 had the highest CIR and the lowest LFS. These results indicated that AML patients with inv(16) were able to be separated into high-risk and low-risk relapse groups based on peritransplant MRD determined by RQ-PCR-based CBFβ/MYH11. Haplo-HSCT might overcome the negative impact of pre-MRD on patient outcomes compared to MSDT.

Nur mit Berechtigung zugänglich

Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58(18):4173–4179PubMed

Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD, European L (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474. https://doi.org/10.1182/blood-2009-07-235358 CrossRef

Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a cancer and leukemia group B study. J Clin Oncol Off J Am Soc Clin Oncol 23(24):5705–5717. https://doi.org/10.1200/JCO.2005.15.610 CrossRef

Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD (2004) Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol Off J Am Soc Clin Oncol 22(6):1087–1094. https://doi.org/10.1200/JCO.2004.07.012 CrossRef

Zhao XS, Qin YZ, Liu YR, Chang YJ, Xu LP, Zhang XH, Huang XJ (2016) The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Leuk Lymphoma 58:1–9. https://doi.org/10.1080/10428194.2016.1239264 CrossRef

Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR, Sandmaier BM (2015) Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29(1):137–144. https://doi.org/10.1038/leu.2014.173 CrossRefPubMed

Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, Shaw BE (2014) Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant 49(5):679–683. https://doi.org/10.1038/bmt.2014.9 CrossRefPubMed

Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A, Del Principe MI, Consalvo MI, De Fabritiis P, Cudillo L, Picardi A, Franchi A, Lo-Coco F, Amadori S (2003) Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 17(11):2178–2182. https://doi.org/10.1038/sj.leu.2403138 CrossRefPubMed

Kayser S, Benner A, Thiede C, Martens U, Huber J, Stadtherr P, Janssen JW, Rollig C, Uppenkamp MJ, Bochtler T, Hegenbart U, Ehninger G, Ho AD, Dreger P, Kramer A (2016) Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J 6(7):e449. https://doi.org/10.1038/bcj.2016.46 CrossRefPubMedPubMedCentral

10.

Karas M, Steinerova K, Lysak D, Hrabetova M, Jungova A, Sramek J, Jindra P, Polivka J, Holubec L (2016) Pre-transplant quantitative determination of NPM1 mutation significantly predicts outcome of allogeneic hematopoietic stem cell transplantation in patients with normal karyotype AML in complete remission. Anticancer Res 36(10):5487–5498. https://doi.org/10.21873/anticanres.11130 CrossRefPubMed

11.

Corbacioglu A, Scholl C, Schlenk RF, Eiwen K, Du J, Bullinger L, Frohling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Dohner H, Dohner K (2010) Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 28(23):3724–3729. https://doi.org/10.1200/JCO.2010.28.6468 CrossRef

12.

Qin YZ, Xu LP, Chen H, Jiang Q, Wang Y, Jiang H, Zhang XH, Han W, Chen YH, Wang FR, Wang JZ, Zhu HH, Liu YR, Jiang B, Liu KY, Huang XJ (2015) Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leukemia & lymphoma 56(11):3116–3123. https://doi.org/10.3109/10428194.2015.1032964 CrossRef

13.

Tang FF, Xu LP, Zhang XH, Chen H, Chen YH, Han W, Wang Y, Yan CH, Sun YQ, Mo XD, Liu KY, Huang XJ (2018) Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia. Br J Haematol 180(3):448–451. https://doi.org/10.1111/bjh.14340 CrossRefPubMed

14.

Zhao X, Wang Z, Ruan G, Liu Y, Wang Y, Zhang X, Xu L, Huang X, Chang Y (2018) Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Ann Hematol 97(6):967–975. https://doi.org/10.1007/s00277-018-3265-1 CrossRefPubMed

15.

Chang YJ, Zhao XS, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, Chen YH, Han W, Sun YQ, Yan CH, Mo XD, Liu KY, Huang XJ (2017) Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts. Am J Hematol 92(12):E659–E661. https://doi.org/10.1002/ajh.24910 [doi]

16.

Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ (2017) Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol 10(1):134. https://doi.org/10.1186/s13045-017-0502-3 CrossRefPubMedPubMedCentral

17.

Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, Jiang Q, Shi HX, Lu DP (2006) Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38(4):291–297. https://doi.org/10.1038/sj.bmt.1705445 CrossRefPubMed

18.

Huang X, Liu D, Liu K, Xu L, Chen H, Han W, Chen Y, Wang Y, Zhang X (2009) Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 15(1 Suppl):91–94. https://doi.org/10.1016/j.bbmt.2008.10.019 CrossRef

19.

Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ (2012) Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 119(14):3256–3262. https://doi.org/10.1182/blood-2011-09-380386 CrossRefPubMed

20.

Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L, Ruan G, Liu Y, Chen S, Huang X (2009) Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 33(3):384–390. https://doi.org/10.1016/j.leukres.2008.08.026 CrossRefPubMed

21.

Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program. Leukemia 17(12):2318–2357. https://doi.org/10.1038/sj.leu.2403135 CrossRefPubMed

22.

Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17(12):2474–2486. https://doi.org/10.1038/sj.leu.2403136 CrossRefPubMed

23.

Qin YZ, Zhu HH, Jiang Q, Jiang H, Zhang LP, Xu LP, Wang Y, Liu YR, Lai YY, Shi HX, Jiang B, Huang XJ (2014) Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. Leuk Res 38(12):1435–1440. https://doi.org/10.1016/j.leukres.2014.09.017 CrossRefPubMed

24.

Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, Fan ZP, Wu DP, Huang XJ (2015) Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125(25):3956–3962. https://doi.org/10.1182/blood-2015-02-627786 CrossRefPubMed

25.

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196 CrossRefPubMedPubMedCentral

26.

Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107(9):3463–3468. https://doi.org/10.1182/blood-2005-09-3640 CrossRefPubMed

27.

Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MP, Marti JM, Aventin A, Mangues R, Brunet S, Sierra J (2013) Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. Eur J Haematol 91(3):209–218. https://doi.org/10.1111/ejh.12130 CrossRefPubMed

28.

Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079–1089. https://doi.org/10.1056/NEJMoa1112304 CrossRefPubMedPubMedCentral

29.

Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX, Huang XJ (2011) Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 17(6):821–830. https://doi.org/10.1016/j.bbmt.2010.08.023 CrossRef

30.

Kuwatsuka Y, Miyamura K, Suzuki R, Kasai M, Maruta A, Ogawa H, Tanosaki R, Takahashi S, Koda K, Yago K, Atsuta Y, Yoshida T, Sakamaki H, Kodera Y (2009) Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood 113(9):2096–2103. https://doi.org/10.1182/blood-2008-03-145862 CrossRefPubMed

Titel: Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression
verfasst von: Zhao Xiaosu
Cao Leqing
Qin Yazhen
Wang Yu
Zhang Xiaohui
Xu Lanping
Huang Xiaojun
Chang Yingjun
Publikationsdatum: 29.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 1/2019
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3480-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Incidence and treatment outcome of aplastic anemia in Taiwan—real-world data from single-institute experience and a nationwide population-based database

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study

Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient

Langerhans cell histiocytosis associated with classical Hodgkin lymphoma contains BRAF V600E mutation

Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China

Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin